Table 2.
Univariate analysis of predictors for pathologic complete response
| Characteristic | Total (n = 53) | pCR (n = 11) | No pCR (n = 42) | p-value |
|---|---|---|---|---|
| Age (yr) | 1.00 | |||
| ≤60 | 28 (100) | 6 (21.4) | 22 (78.6) | |
| >60 | 25 (100) | 5 (20.0) | 20 (80.0) | |
| Gender | 0.07 | |||
| Male | 37 (100) | 5 (13.5) | 32 (86.5) | |
| Female | 16 (100) | 6 (37.5) | 10 (62.5) | |
| Performance status | 0.18 | |||
| ECOG 0 | 25 (100) | 3 (12.0) | 22 (88.0) | |
| ECOG 1 | 28 (100) | 8 (28.6) | 20 (71.4) | |
| Smoking | 0.74 | |||
| Non-smoker | 25 (100) | 6 (24.0) | 19 (76.0) | |
| Smoker | 28 (100) | 5 (17.9) | 23 (82.1) | |
| Differentiation | 0.02 | |||
| WD and MD | 49 (100) | 8 (16.3) | 41 (83.7) | |
| PD and UD | 4 (100) | 3 (75.0) | 1 (25.0) | |
| Distan ce from AV (cm) | 0.33 | |||
| ≤6 | 26 (100) | 4 (14.8) | 23 (85.2) | |
| >6 | 27 (100) | 7 (26.9) | 19 (73.1) | |
| Mass size (cm) | 0.18 | |||
| ≤5 | 17 (100) | 7 (20.0) | 28 (80.0) | |
| >5 | 36 (100) | 4 (22.2) | 14 (77.8) | |
| Circumference (%) | 1.00 | |||
| <100 | 25 (100) | 6 (24.0) | 19 (76.0) | |
| 100 | 28 (100) | 5 (17.9) | 23 (82.1) | |
| Initial CEA level (ng/dL) | 0.10 | |||
| ≤5 | 30 (100) | 7 (23.3) | 23 (76.7) | |
| >5 | 22 (100) | 3 (13.6) | 19 (86.4) | |
| Unknown | 1 (100) | 1 (100) | 0 (0) | |
| Elevation of CEA level | 0.12 | |||
| Elevation | 27 (100) | 4 (16.0) | 21 (84.0) | |
| No elevation | 25 (100) | 6 (22.2) | 21 (77.8) | |
| Unknown | 1 (100) | 1 (100) | 0 (0) | |
| Initial Hb level (g/mL) | 1.00 | |||
| <10 | 7 (100) | 1 (14.3) | 6 (85.7) | |
| ≥10 | 46 (100) | 10 (21.7) | 36 (78.3) | |
| Clinical T stage | 0.10 | |||
| T2 | 12 (100) | 5 (41.7) | 7 (58.3) | |
| T3, T4 | 41 (100) | 6 (14.6) | 35 (85.4) | |
| Lymph node involvement | 0.72 | |||
| N (–) | 16 (100) | 4 (25.0) | 12 (75.0) | |
| N (+) | 37 (100) | 7 (18.9) | 30 (81.1) | |
| Total dose of radiotherapy (Gy) | 0.11 | |||
| <50.4 | 3 (100) | 2 (66.7) | 1 (33.3) | |
| ≥50.4 | 50 (100) | 9 (18.0) | 41 (82.0) | |
| Post-CCRT colonoscopy | 0.62 | |||
| Improved | 37 (100) | 9 (24.3) | 28 (75.7) | |
| Not improved | 8 (100) | 1 (12.5) | 7 (87.5) | |
| Unknown | 8 (100) | 1 (12.5) | 7 (87.5) | |
| Post-CCRT CEA (ng/dL) | 0.26 | |||
| ≤5 | 45 (100) | 10 (22.2) | 35 (77.8) | |
| >5 | 6 (100) | 0 (0) | 6 (100) | |
| Unknown | 2 (100) | 1 (50.0) | 1 (50.0) | |
| Interval from CCRT to operation (wk) | 0.04 | |||
| <7 | 26 (100) | 2 (7.7) | 24 (92.3) | |
| ≥7 | 27 (100) | 9 (33.3) | 18 (66.7) |
Values are presented as number (%).
pCR, pathologic complete response; ECOG, Eastern Cooperative Oncology Group; WD and MD, well and moderate differentiated; PD and UD, poorly and undifferentiated; AV, anal verge; CEA, carcinoembryonic antigen; Hb, hemoglobin; CCRT, concurrent chemoradiotherapy.